Pharmacogenomic Data and Labeling: A Less-Safe Harbor for Existing Drugs?

At the same time that FDA is taking pains to assure companies that pharmacogenomics data won't affect the review process for new drugs unless the agency and the sponsor first agree on the meaning of those data, it's also thinking of taking a tougher position with existing drugs.

At the same time that the FDA is taking pains to assure companies that pharmacogenomics data won't affect the review process for new drugs unless the agency and the sponsor first agree on the meaning of those data, it's thinking of taking a tougher position with existing drugs. The FDA is in the midst of considering the appropriate standards for reviewing labels of existing drugs to see if they should now include pharmacogenomics data that would better inform physician prescribing decisions. And the agency appears to be contemplating a threshold for review that is lower than the level of adverse event reporting that would trigger a review for the purposes of recalling a compound.

For some time, FDA officials have been ratcheting up efforts to work with industry to determine the appropriate uses for...

More from Archive

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.